Last €43.40 EUR
Change Today +0.55 / 1.29%
Volume 200.0
As of 11:45 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GS7A) Snapshot

Open
€42.70
Previous Close
€42.85
Day High
€43.52
Day Low
€42.16
52 Week High
03/5/15 - €43.52
52 Week Low
10/16/14 - €32.40
Market Cap
105.6B
Average Volume 10 Days
262.6
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
02/18/15
P/E TM
--
Dividend
€2.70
Dividend Yield
4.74%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GS7A)

glaxosmithkline plc-spon adr (GS7A) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

97,921 Employees
Last Reported Date: 02/26/15
Founded in 1935

glaxosmithkline plc-spon adr (GS7A) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.0M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.2M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $2.3M
Compensation as of Fiscal Year 2014.

glaxosmithkline plc-spon adr (GS7A) Key Developments

GlaxoSmithKline To Sell Nicotinell Business

GlaxoSmithKline plc (LSE:GSK) intends to sell its Australian nicotine chewing gum business, Nicotinell, with indicative bids being expected before the end of March 2015. GlaxoSmithKline engaged Greenhill globally to sell several assets including the Nicotinell brand and smoking cessation products supplied in Australia under private-label arrangements.

GlaxoSmithKline plc Announces Board Changes

GlaxoSmithKline plc announced that Sir. Christopher Gent will step down as Chairman of GSK at the company's Annual General Meeting on 7 May 2015. He will be succeeded by Sir. Philip Hampton with effect from the end of the AGM. Si.r Philip joined GSK's Board as an independent Non-Executive Director on 1 January 2015, and will become Deputy Chairman on 1 April 2015. Sir. Philip chairs the company's Nominations Committee. He will remain Chairman of RBS until 31 August 2015. In addition, Tom de Swaan, independent Non Executive Director, is not seeking re-election to the Board at the AGM. He has been a Board member for 9 years and is currently Chairman of the Remuneration Committee and a member of the Audit & Risk Committee (of which he was previously Chairman), and the Nominations Committee. A successor for Mr. de Swaan as Chairman of the Remuneration Committee will be announced in due course. Jing Ulrich has decided not to stand for re-election to the Board at the AGM.

Insulet Corporation Announces Distribution Agreement with Glaxosmithkline

Insulet Corporation announced that following a four year distribution agreement with GlaxoSmithKline (GSK), the Company will assume full rights to distribute the OmniPod System in the Canadian market via a newly created Canadian Subsidiary, Insulet Canada Corporation. This will include all sales, marketing, training and support activities. The transfer is expected to be complete by end of June 2015. According to the Canadian Diabetes Association, there are approximately 3.3 million Canadians currently living with diabetes. 1 About 5% to 10% of people living with diabetes have type 1 diabetes, which is always treated with insulin. Insulet and GSK are working collaboratively to help ensure a seamless experience for all OmniPod users and healthcare providers during this transition, with the aim to keep all existing services intact.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7A:GR €43.40 EUR +0.55

GS7A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $167.58 USD +0.42
Amgen Inc $159.88 USD +0.69
Bristol-Myers Squibb Co $66.09 USD +0.416
Novo Nordisk A/S kr318.00 DKK +2.40
Sanofi €87.84 EUR +0.39
View Industry Companies
 

Industry Analysis

GS7A

Industry Average

Valuation GS7A Industry Range
Price/Earnings 27.0x
Price/Sales 3.2x
Price/Book 17.3x
Price/Cash Flow 27.0x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.